corporate_fare

Inhibikase Therapeutics Inc.

Address: 3350 Riverwood Parkway Southeast # 1900

Sponsor Overview

assignment

Specializations

Pulmonary Arterial Hypertension

Research activity is centered on pulmonary arterial hypertension, with clinical interest in adult WHO Group 1 PAH and treatment strategies used alongside established background therapy. The sponsor’s work in this area reflects a focus on the management of pulmonary vascular disease and related cardiopulmonary impairment.

WHO Group 1 pulmonary arterial hypertension
Background PAH therapy
Cardiopulmonary vascular disease

The clinical program is aligned with therapeutic development in rare cardiovascular disorders affecting pulmonary circulation and right heart function.

Cardiovascular and Pulmonary Vascular Medicine

The sponsor’s trial portfolio indicates an emphasis on diseases at the intersection of cardiology and pulmonology, particularly conditions involving elevated pulmonary arterial pressure and vascular remodeling. This places its research within the broader domain of pulmonary vascular medicine.

Cardiopulmonary hemodynamics
Pulmonary vascular remodeling
Right ventricular strain

Its clinical interest is concentrated on therapeutic approaches relevant to long-term disease control in chronic vascular lung disease.

Therapeutic Development in Rare Disease

Inhibikase Therapeutics Inc. is engaged in rare disease research through a program focused on pulmonary arterial hypertension, a serious and specialized condition requiring targeted treatment options. The sponsor’s activity supports the development of therapies for patients with limited treatment choices in orphan cardiovascular disease.

Rare cardiovascular disease
Orphan disease therapeutics
Specialty cardiovascular care

This area of interest is directed toward improving management options for a complex chronic disorder with substantial functional impact.

Clinical Trial Activity in Multinational Settings

The sponsor’s research is supported by a network of collaborating sites across multiple countries, indicating active clinical involvement in international trial operations for pulmonary arterial hypertension. This geographic reach reflects sustained interest in enrolling patients within diverse cardiovascular research settings.

Multinational clinical research
Specialist investigational sites
Adult PAH patient populations

The trial landscape is concentrated on a single therapeutic area, with research activity directed toward advanced pulmonary hypertension care.

Trial Name	Country	Status
Efficacy and Safety of IKT-001 in Adults with WHO Group 1 Pulmonary Arterial Hypertension: An Adaptive, Randomized, Double-Blind, Placebo-Controlled Trial	Austria Belgium Czechia Denmark France Germany Greece Ireland Italy Latvia Lithuania Poland Portugal Spain The Netherlands	Not Yet Recruiting